Preliminary results from a phase I expansion study of ZG005, a bispecific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors

被引：0
|
作者：
Qin, Shukui
Cheng, Ying
Wang, Qiming
Cheng, Shuxia
Chai, Xiaoli
Wu, Lihua
Yu, Yan
Shi, Jianhua
Li, Xiumin
Fan, Lianlian
Xia, Jin
Huang, Yisheng
Ji, Yinghua
Zhuang, Zhixiang
Yang, Lei
Jiang, Ou
Zheng, Qinhong
Liao, Sihai
Yi, Shanyong
Ye, Huangyang
机构：
[1] Nanjing Chinese Med Univ, Jinling Hosp, Canc Ctr, Nanjing, Peoples R China
[2] Jilin Canc Hosp, Changchun, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[4] Henan Canc Hosp, Zhengzhou, Peoples R China
[5] ChangSha TaiHe Hosp, Changsha, Peoples R China
[6] Shulan (Hangzhou) Hosp, Hangzhou, Peoples R China
[7] Harbin Med Univ, Internal Med Dept 6, Canc Hosp, Harbin, Peoples R China
[8] Linyi Canc Hosp, Linyi, Shandong, Peoples R China
[9] Linyi Canc Hosp, Dept Gynecol Oncol, Linyi, Shandong, Peoples R China
[10] Deyang Peoples Hosp, Deyang, Peoples R China
[11] Anyang Tumor Hosp, Anyang, Henan, Peoples R China
[12] Maoming Peoples Hosp, Dept Oncol, Maoming, Peoples R China
[13] Xinxiang Med Univ, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China
[14] Soochow Univ, Dept Oncol, Affiliated Hosp 2, Suzhou, Peoples R China
[15] Nantong Canc Hosp, Nantong, Peoples R China
[16] Second Peoples Hosp Neijiang, Neijiang, Peoples R China
[17] Peoples Hosp Quzhou, Quzhou, Peoples R China
[18] Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China
[19] Zhengzhou Cent Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
[20] Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2611
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-in-human study of ZG005, a dual specific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors
    Qin, Shukui
    Cheng, Ying
    Wu, Lihua
    Chai, Xiaoli
    Wang, Qiming
    Liu, Qinghua
    Fan, Lianlian
    Shi, Jianhua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Preclinical pharmacology and safety studies of ZG005: an anti-PD-1/TIGIT bispecific mAb in a phase I clinical trial for advanced tumors
    Zhu, Bing
    Dai, Tongcheng
    Liu, Ruifeng
    Suarez, Alfonso
    Liban, Tyler
    Zhang, Bin
    Karow, Margaret
    Sheng, Jackie
    Sheng, Zelin
    Lv, Binhua
    CANCER RESEARCH, 2023, 83 (07)
  • [3] Phase I/II safety and preliminary efficacy of PM1022, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors
    Xue, Junli
    Zhang, Yan
    Hu, Xudong
    Zhao, Wei
    Sun, Yuping
    Li, Qun
    Jin, Xiaoying
    Xue, Liqiong
    Ge, Xiaoxiao
    Lin, Fengjuan
    Tang, Wenbo
    Zhou, Jiuli
    Guo, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Phase I safety and preliminary efficacy of PM1009, a bispecific antibody targeting TIGIT and PVRIG, in patients with advanced solid tumors
    Xue, Liqiong
    Wu, Lihua
    Tang, Wenbo
    Wang, Zhuoyi
    Xue, Junli
    Li, Qun
    Ge, Xiaoxiao
    Lin, Fengjuan
    Zhao, Wei
    Zhou, Jiuli
    Guo, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors
    Liu, Jiajian
    Zhou, Caicun
    Li, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors
    Day, D.
    Ganju, V.
    Chung, K.
    Si, L.
    Mao, L.
    Aghmesheh, M.
    Hoyer, R.
    Brewin, K.
    Zeng, S.
    Lu, Q.
    Jiang, C.
    Ren, F.
    Wu, X.
    Guo, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S625 - S625
  • [7] PHASE I STUDY OF ANTI PD-1 ANTIBODY ONO-4538 IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Yamamoto, N.
    Nokihara, H.
    Yamada, Y.
    Asahina, H.
    Shibata, T.
    Tamura, Y.
    Seki, Y.
    Honda, K.
    Tanabe, Y.
    Wakui, H.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 26 - 26
  • [8] Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD-1 and VEGF, in Chinese Patients With Advanced Solid Tumors
    Wang, Fenghua
    Wei, Xiaoli
    Zheng, Yulong
    Wang, Jing
    Ying, Jieer
    Chen, Xiaozhong
    Luo, Suxia
    Luo, Huiyan
    Yu, Xufang
    Chen, Benchao
    Ma, Lei
    Xu, Ruihua
    CANCER MEDICINE, 2025, 14 (06):
  • [9] Phase I safety and preliminary efficacy of PM1003, a bispecific antibody targeting PD-L1 and 4-1BB, in patients with advanced solid tumors
    Xue, Junli
    Sun, Yuping
    Li, DaPeng
    Guo, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors
    Markman, Ben
    Tran, Ben
    Gan, Hui
    Prawira, Amy
    Coward, Jermaine
    Jin, Xiaoping
    Li, Baiyong
    Wang, Max
    Xia, Yu
    Desai, Jayesh
    Millward, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
12345